Oxford Immunotec (OXFD) Reports Q4 Revenues Above Estimates; Offers FY19 Revenue Mid-Point Guidance Above Consensus

Oxford Immunotec (NASDAQ: OXFD) reported Q4 EPS of $5.23, versus $0.33 reported last year. Revenue for the quarter came in at $15.4 million versus the consensus estimate of $15.1 million.

GUIDANCE:

Oxford Immunotec sees FY2019 revenue of $69-72 million, versus the consensus of $69.85 million.

For earnings history and earnings-related data on Oxford Immunotec (OXFD) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• Fabrinet (FN) Tops Q4 EPS by 29c, Beats on Revenue; Offers Guidance
• Bath & Body Works rises as Citi upgrades stock ahead of earnings